



DATE: February 22 2024
TO: Commonwealth of Kentucky Medicaid Pharmacy Network
FROM: MedImpact Healthcare Systems
Subject: **Lagevrio™ Reimbursement KY MCO Program**

Lagevrio™ (molnupiravir) has been authorized for treatment of adults aged 18 years and older with a current diagnosis of mild to moderate COVID-19 who are at high risk for progressing to severe COVID-19 including hospitalization or death, and for whom alternative COVID-19 treatment options authorized or approved by the U.S. Food and Drug Administration (FDA) are not accessible or clinically appropriate.

In November 2023, distribution switched from government-managed to traditional commercial distribution. MedImpact has updated the pricing algorithm to allow ingredient cost reimbursement for the NDC distributed through commercial vendors. The table below provides both the government-distributed and commercially distributed EUA product NDCs for provider reference. Providers should continue to dispense the government-provided EUA product until their supply is exhausted.

Prescriptions dispensed using the commercially distributed product **for Kentucky Managed Care members** prior to February 8, 2024, may be reversed and reprocessed to include the ingredient cost in the final paid amount. Providers who do not reprocess previously submitted claims will be automatically reprocessed in the next 60 days by MedImpact. Claims for members enrolled in Kentucky Medicaid Fee-for-Service were not impacted by this update.

NDC	Label Name	Ingredient Cost Reimbursed
00006-5055-09	Lagevrio (EUA) 200mg	Yes
00006-5055-06	Lagevrio (EUA) 200mg	No



KY MCO Contact Information

Program Questions	KYMCOPBM@MedImpact.com
Pharmacy Help Desk	(800) 210-7628 [24 hours per day/ 7 days per week]
Prior Authorizations	Phone (844) 336-2676 [8:00AM - 7:00PM EST/ 7 days per week];Fax (858) 357-2612
Pharmacy Portal	https://kyportal.medimpact.com/
BIN: 023880 / PCN: KYPROD1 / GROUP: KYM01	